Skip to main content

Table 3 Clinicopathologic characteristics of patients with acute myeloid leukemia treated with prophylactic micafungin or posaconazole at SNUH

From: Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy

Patient characteristics Micafungin
(n = 32)
Posaconazole
(n = 39)
P -value
Median age, years (range) 57 (21–84) 52 (18–73) 0.408
Sex, n (%)
 Male 18 (56.3) 19 (48.7)  
 Female 14 (43.8) 20 (51.3) 0.527
Disease, n (%)
 De novo AML 23 (71.9) 33 (84.6) 0.191
 Secondary AML 9 (28.1) 6 (15.4)  
Induction chemotherapy, n (%)
 AID-based regimen 29 (90.6) 32 (82.1) 0.495
 Modified FLAI 3 (9.4) 7 (17.9)  
Median BM blast percentage at diagnosis (range) 62.6 (12.9–95.4) 32.2 (17.7–99.0) 0.020
Median duration of micafungin treatment, days (range) 26.0 (1.0–68.0) 25.0 (7.0–95.0) 0.782
Median time from chemotherapy to severe neutropenia, days (range) 28.5 (11.0–84.0) 28.0 (7.0–139.0) 0.776
  1. Abbreviations: AML Acute myeloid leukemia, AID Cytarabine + idarubicin, FLAI Fludarabine + cytarabine + idarubicin, BM Bone marrow